ABBV acquisition of Apogee Therapeutics

On June 22, AbbVie Inc. (NYSE:ABBV) announced a definitive agreement to acquire Apogee Therapeutics (NASDAQ:APGE) for approximately $10.9 billion in an all-cash transaction, valuing APGE shares at over $135 each. This acquisition adds a pipeline of clinical-stage therapies for inflammatory and immunological diseases to AbbVie's portfolio, including atopic dermatitis and asthma treatments.

The deal drives a significant surge in APGE's stock price, up 46.66% on June 22, and a 6.25% increase in ABBV shares the same day. It also strengthens AbbVie's long-term growth outlook, leading Canaccord to raise its price target on ABBV to $273 and reiterate a 'Buy' rating. AbbVie, already among the top blue-chip stocks with growing dividends, further solidifies its position in the immunology space.

Next, investors should watch for the deal's closure, expected in Q4 2022 or early 2023. Additionally, the progress of Apogee's pipeline, particularly its lead asset zumilokibart, will be crucial. AbbVie's Q2 earnings, scheduled for late July, may provide further insights into the company's strategic vision post-acquisition.